Healthcare Professionals
Reveal LINQ
Insertable Cardiac Monitoring System
Adriatic
Argentina
Asia-Pacific
Australia and New Zealand
Bangladesh
Belgique (Belgium)
België (Belgium)
Brasil (Brazil)
Bulgaria
Canada
Canada
Česká republika (Czech Republic)
Chile
中国 (China)
Colombia
Costa Rica
Србија (Serbia)
Danmark (Denmark)
Deutschland (Germany)
Ecuador
España (Spain)
Europe
France
Ελλάδα (Greece)
香港特区 (Hong Kong SAR)
Indian Subcontinent
Ireland
Israel ישראל
Italia (Italy)
日本 (Japan)
Latinoamérica
Magyarország (Hungary)
México (Mexico)
Middle East and North Africa
Nederland (Netherlands)
Norge (Norway)
Österreich (Austria)
Panama
Portugal
Paraguay
Perú (Peru)
Polska (Poland)
Российская Федерация (Russia)
Puerto Rico
Romania
Schweiz (Switzerland)
Slovenská republika (Slovak Republic)
Southeast Asia
South Africa and Sub-Sahara
대한민국 (South Korea)
Suisse (Switzerland)
Suomi (Finland)
Sverige (Sweden)
台湾地区 (Taiwan)
Türkiye (Turkey)
United Kingdom
United States
Uruguay
Україна (Ukraine)
OVERVIEW
The World's Smallest, Most Accurate Insertable Cardiac Monitor1
The Reveal LINQ™ Insertable Cardiac Monitor is a wireless and powerfully small insertable cardiac monitor ideal for patients experiencing infrequent symptoms that require long-term monitoring or ongoing management.
An Advanced Monitoring Solution
DEVICE LONGEVITY THAT OPTIMIZES DIAGNOSTIC YIELD
INDICATIONS
The Reveal LINQ Insertable Cardiac Monitor is an implantable patient-activated and automatically-activated monitoring system that records subcutaneous ECG and is indicated in the following cases:
- patients with clinical syndromes or situations at increased risk of cardiac arrhythmias
- patients who experience transient symptoms such as dizziness, palpitation, syncope and chest pain, that may suggest a cardiac arrhythmia.
This device has not been specifically tested for pediatric use.
PRODUCT DETAILS
THE REVEAL LINQ SYSTEM ADVANTAGE
Actionable data to diagnose and treat even the most difficult-to-detect arrhythmias
UNMATCHED ACCURACY
Device innovations that provide leading detection accuracy
SUPERIOR EVIDENCE
Clinical rigor that guides decisions across multiple conditions
SIMPLIFIED MONITORING
Exclusive solutions that offer new freedom to focus on patients
UNMATCHED ACCURACY
Device innovations that provide leading detection accuracy
DRIVING ACCURACY EVOLUTION
Dedicated to advancing accuracy with every device generation
Industry-Leading TruRhythm Algorithms
Our newest detection algorithms streamline episodes without sacrificing sensitivity
Smart Filtering
Second sensing filter analyzes rhythms for possible undersensing in Brady and Pause
Self-learning
AF algorithm learns and adapts to patients with sinus arrhythmia
SUPERIOR ACCURACY IN AF DETECTION
Demonstrating superior atrial fibrillation detection accuracy through our performance results*
Advanced AF Detection
Streamlined Episode Review
*Disclaimer: A controlled, head-to-head study evaluating the comparative performance of these devices has not been done.
SUPERIOR EVIDENCE
Clinical rigor that guides decisions across multiple conditions
MOST STUDIED
Evidence portfolio that includes 500+ published clinical articles and abstracts9
MOST VALIDATED
Clinical validation across cryptogenic stroke, syncope, and atrial fibrillation3,8,10
MOST UTILIZED
Data leveraged by clinical societies to develop treatment guidelines across indications11,12
CRYPTOGENIC STROKE
2016 ESC Guidelines for the Management of AF11
Long-term insertable cardiac monitoring recommended for cryptogenic stroke patients to document silent AF.
CRYSTAL AF Study3
Short- and intermediate-term cardiac monitoring may miss many patients with paroxysmal AF.
is the median time to AF detection in Cryptogenic Stroke patients
of patients who had AF would have been missed if only monitored for 30 days
SYNCOPE
more likely to reach a diagnosis with ICM than standard of care13
of Reveal ICM patients with syncope recurrence received a differential diagnosis10
SYNCOPE
2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients with Syncope12
Insertable cardiac monitoring recommended for syncope patients with
infrequent symptoms > 30 days apart.
2018 ESC Guidelines for the Diagnosis and Management of Syncope13
Insertable cardiac monitoring recommended for early monitoring in low-risk syncope patients and after workup of high-risk patients.
ATRIAL FIBRILLATION
Reveal AF Study14
AF detection increases over time for patients at high risk for AF and stroke.
AF detection rate at 30 months
of patients with AF would have been missed if only monitored for 30 days
SIMPLIFIED MONITORING
FREEDOM TO FOCUS ON BETTER PATIENT CARE
Exclusive solutions keep you connected to your patients, while turning device data into actionable insights
APP-BASED INSERTION WORK FLOW
Reveal LINQ Mobile Manager
Manage device registration, activation, CareLink™ pre-enrollment and patient education — right from your tablet.
MORE EFFICIENT DATA MANAGEMENT
Enhanced CareLink™ Network
Move critical transmissions to the forefront and assess/adjudicate episodes right from the improved Quick Look™ page.
A VIRTUAL EXTENSION OF YOUR CLINICAL TEAM
Reveal LINQSM Monitoring Service
Streamline patient management with support from certified technicians who ensure ongoing data transmission, review cardiac data, and provide clinically actionable reports.
MANUALS AND TECHNICAL GUIDES
Access prescriber, implant, MRI, and other manuals on the Medtronic Manual Library. Search by the product name (Reveal LINQ) or model number (LNQ11). You may also call 800-961-9055 for a copy of a manual.
MODEL SPECS
Reveal LINQ LNQ11 Specifications
| DESCRIPTION | SPECS |
|---|---|
|
Volume |
1.2 cc |
|
Dimensions |
44.8 mm x 7.2 mm x 4.0 mm |
|
Mass |
2.5 g ± 0.5 |
|
Distance between electrodes |
37.7 mm |
|
MRI Compatibility |
3.0 and 1.5 Tesla with no post-insertion waiting period required* |
|
Battery Longevity |
Projected 3 Years2 |
1
ICM Competitive Comparison Guide. Medtronic data on file. 2017.
2
Reference the Reveal LINQ ICM Clinician Manual for usage parameters.
3
Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. June 26, 2014;370(26):2478-2486.
4
Furukawa T, Maggi R, Bertolone C, Fontana D, Brignole M. Additional diagnostic value of very prolonged observation by implantable loop recorder in patients with unexplained syncope. J Cardiovasc Electrophysiol. January 2012;23(1):67-71.
5
TruRhythm Detection Algorithms. Medtronic data on file. 2017.
6
Nölker G, Mayer J, Boldt LH, et al. Performance of an Implantable Cardiac Monitor to Detect Atrial Fibrillation: Results of the DETECT AF Study. J Cardiovasc Electrophysiol. December 2016;27(12):1403-1410.
7
Biotronik BioMonitor 2 Clinical Manual. 2016.
8
Sanders P, Pürerfellner H, Pokushalov E, et al. Performance of a new atrial fibrillation detection algorithm in a miniaturized ICM: Results from the Reveal LINQ Usability Study. Heart Rhythm. July 2016;13(7):1425-1430.
9
Medtronic Reveal Publications. Medtronic data on file. 2016.
10
Edvardsson N, Frykman V, van Mechelen R, et al. Use of an implantable loop recorder to increase the diagnostic yield in unexplained syncope: results from the PICTURE registry. Europace. February 2011;13(2):262-269.
11
Kirchhof P, Benussi, S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. October 7, 2016;37(38):2893-2962.
12
2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
13
Brignole M, Moya A, de Lange FJ, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. June 1, 2018;39(21):1883-1948.
14
Reiffel JA, Verma A, Kowey PR, et al. High Incidence of Previously Unknown (“Silent”) Atrial Fibrillation in Patients at High Risk for Atrial Fibrillation and Stroke: Primary Results from the REVEAL AF Study. Abstract presented at Heart Rhythm Society Annual Scientific Sessions. 2017.